First triple combination MDI licensed for asthma
Summary page details a snapshot of the evidence for Trimbow (beclometasone, formoterol, and glycopyrronium), metered-dose inhaler. It is licensed for maintenance treatment of asthma in adults who are not adequately controlled on a LABA and medium dose of ICS.
Source:
Monthly Index of Medical Specialities
SPS commentary:
NICE Guideline NG80 (Asthma: diagnosis, monitoring and chronic asthma management) advises that if asthma is uncontrolled in adults on a moderate maintenance inhaled corticosteroid dose with a long acting beta agonist a trial of a long-acting muscarinic receptor antagonist (such as glycopyrronium) can be considered as an alternative to increasing the inhaled corticosteroid to a high maintenance dose.